Ohm wrote, For best possible trial outcome both s
Post# of 148158
Quote:
For best possible trial outcome both single allele and double allele deletions should be excluded but the FDA might frown upon that.
I thought double allele and single allele deletions were only (respectively) 1% and 9% of the European population, and therefore would be even less than that in the U.S. Why would the FDA forbid an exclusion of a fairly small percentage of the population?